Host responses to pathogenic Escherichia coli

Pathogenic Escherichia coli in Latin America

Volumn , Issue , 2010, Pages 122-141

  Ibarra, Cristina ^a   Palermo, Marina ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872917865     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805192211001010122     Document Type: Chapter

References (199)

1. Frankel G, Phillips AD, Rosenshine I, et al. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol. 1998;30:911-21. Review.
2. Notario R, Borda N, Gambande T, et al. Species and serovars of enteropathogenic agents associated with acute diarrheal disease in Rosario, Argentina. Rev Inst Med Trop Sao Paulo. 1996;38:5-7.
3. Cravioto A, Trujillo F, León LA, et al. Infections caused by enteropathogenic Escherichia coli. Gac Med Mex. 1996;132:611-5.
4. Gascon J. Epidemiology, Etiology and pathophysiology of traveler's diarrhea. Digestion. 2006;73:102-8.
5. Qadri F, Svennerholm AM, Faruque AS, et al. Enterotoxigenic Escherichia coli in developing countries: Epidemiology, Microbiology, Clinical features, treatment, and prevention. Clin Microbiol Rev. 2005;18:465-83.
6. Eckmann L. Small bowel infections. Curr Opin Gastroenterol. 2002;18:197-02.
7. Turner SM, Scott-Tucker A, Cooper LM, et al. Weapons of mass destruction: virulence factors of the global killer Enterotoxigenic Escherichia coli. FEMS Microbiol Lett. 2006;263:10-20. Minireview.
8. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol. 2010;8:26-38. Review.
9. Karmali MA, Steele BT, Petric M, et al. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1:619-20.
10. Kaper JB. Enterohemorrhagic Escherichia coli. Curr Opin Microbiol. 1998;1:103-08.
11. Gianantonio CA, Vitacco M, Mendilaharzu F, et al. The hemolytic-uremic syndrome. Nephron. 1973;11:174-92.
12. Rivas M, Miliwebsky E, Chinen I, et al. Case-Control Study Group. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis. 2006;3:88-96.
13. Roldgaard BB, Scheutz F, Boel J, et al. VTEC O157 subtypes associated with the most severe clinical symptoms in humans constitute a minor part of VTEC O157 isolates from Danish cattle. Int J Med Microbiol. 2004;294:255-59.
14. Luperchio S, Schauer DB. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect. 2001;3:333-340.
15. McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol. 1997;23:399-07.
16. Coburn B, Sekirov I, Finlay BB. Type III Secretion Systems and Disease. Clinic Microbiol Rev. 2007,20:535-49.
17. Campellone K, Rankin S, Pawson T, et al. Clustering of Nck by a 12-residue Tir phosphopeptide is sufficient to trigger localized actin assembly. J Cell Biol. 2004;164:407-15.
18. Lebeis SL, Powell KR, Merlin D, et al. Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun. 2009;77:604-14.
19. Pistone Creydt V, Venzano A, Vilte D, et al. Cytotoxic effect in human colon of enterohemorrhagic Escherichia coli isolated from calves with bloody diarrhea. Rev Arg Microbiol. 2005;37:117-21
20. Caron E, Crepin VF, Simpson N, et al. Subversion of actin dynamics by EPEC and EHEC. Curr Opin Microbiol. 2006;9:40-45.
21. Viswanathan VK, Hodges K, Hecht G. Enteric infection meets intestinal function: how bacterial pathogens cause diarrhoea. Nat Rev Microbiol. 2009;7:110-19.
22. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-93.
23. Guttman JA, Li Y, Wickham M, et al. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell Microbiol. 2006;8:634-45.
24. Viswanathan V, Koutsouris A, Lukic S, et al. Comparative analysis of EspF from enteropathogenic and enterohemorrhagic Escherichia coli in alteration of epithelial barrier function. Infect Immun. 2004;72:3218-27.
25. Tomson F, Viswanathan V, Kanack K, et al. Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. Mol Microbiol. 2005;56:447-64.
26. Ma C, Wickham ME, Guttman JA, et al. Citrobacter rodentium infection causes both mitochondrial dysfunction and intestinal epithelial barrier disruption in vivo: role of mitochondrial associated protein (Map). Cell Microbiol. 2006;8:1669-86.
27. Guttman JA, Samji FN, Li Y, et al. Aquaporins contribute to diarrhoea caused by attaching and effacing bacterial pathogens. Cell Microbiol. 2007;9:131-41.
28. Silberstein C, Kierbel A, Amodeo G, et al., Zotta E, Bigi F, Berkowski D, Ibarra C. Functional characterization and localization of AQP3 in the human colon Brazilian J Med Biol Res. 1999;32:1303-13.
29. Tsujikawa T, Itoh A, Fukunaga T, et al. Alteration of aquaporin mRNA expression after small bowel resection in the rat residual ileum and colon. J Gastroenterol Hepatol. 2003;18:803-08.
30. Philpott DJ, Ackerley CA, Kiliaan AJ, et al. Traslocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am J Physiol. 1997;273:G1349-G1358.
31. Schüller S, Frankel G, Phillips AD. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damages in organ culture. Cell Microbiol. 2004;6:289-301.
32. Acheson D, Moore R, De Breucker S, et al. Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun. 1996;64:3294-4000.
33. Müthing J, Schweppe CH, Karch H, et al. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 2009;101:252-64.
34. Imai Y, Fukui T, Kurohane K, et al. Restricted expression of Shiga toxin binding sites on mucosal epithelium of mouse distal colon. Infect Immun. 2003;71:985-90.
35. Rodney A, Moxley L, Francis DH. Overview of animal models. In Kaper JB & O ́Brien AD Eds. Escherichia coli O157:H7 and other Shiga toxin-producing E coli strains. Am Soc Microbiol. Washington DC. 1998;p249-260.
36. Keenan KP, Sharpnack DD, Collins H, et al. Morphologic evaluation of the effects of Shiga toxin and E coli Shiga-like toxin on the rabbit intestine. Am J Pathol. 1986;125:69-80.
37. Fiorito P, Burgos JM, Fernandez Miyakawa M, et al. Effect of Shiga toxin 2 on water and ion transport in human colon in vitro. Dig Dis Sci. 2000;45:480-86.
38. Pistone Creydt V, Martín F, Fernández Miyakawa M, et al. Shiga toxin 2B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. Braz J Med Biol Res. 2004;37:799-08.
39. Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect. 2004;6:1388-94.
40. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2- complex. Microbes Infect. 2004;6:1361-7.
41. Khan MA, Ma C, Knodler LA, et al. Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect Immun. 2006;74:2522-36.
42. Gibson DL, Ma C, Rosenberger CM, et al. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol. 2008;10:388-03.
43. Pull SL, Doherty JM, Mills JC, et al. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci. USA. 2005;102:99-04.
44. Calderon Toledo C, Rogers TJ, et al. Shiga Toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol. 2008,173:1428-39.
45. Maaser C, Housley MP, Iimura M, et al. Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies. Infect Immun. 2004;72:3315-24.
46. Donnenberg MS, Tacket CO, Losonsky G, et al. Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge. Infect Immun. 1998;66:52-58.
47. Mumy KL, McCormick BA. The role of neutrophils in the event of intestinal inflammation. Curr Opin Pharmacol. 2009;9:697-01.
48. Kelsall BL. Innate and adaptive mechanisms to control [corrected] pathological intestinal inflammation. J Pathol. 2008;214:242-59.
49. Besser RE, Griffin PM, Slutsker L. Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Ann Rev Med. 1999;50:355-67.
50. Thorpe CM, Hurley BP, Lincicome LL, et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immun. 1999;67:5985-93.
51. Thorpe CM, Smith WE, Hurley BP, et al. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect Immun. 2001;69:6140-47.
52. Yu J, Kaper JB. Cloning and characterization of the eae gene of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol. 1992;6:411-17.
53. Yamasaki C, Natori Y, Zeng XT, et al. Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity. FEBS Lett. 1999;442:231-34.
54. Berin MC, Darfeuille-Michaud A, Egan LJ, et al. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-κB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol. 2002;4:635-48.
55. Zhou X, Giron JA, Torres AG, et al. Flagellin of enteropathogenic Escherichia coli stimulates interleukin-8 production in T84 cells. Infect Immun. 2003;71:2120-29.
56. Miyamoto Y, Iimura M, Kaper JB, et al. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signaling of human colon epithelium in vivo. Cell Microbiol. 2006;8:869-79.
57. Eckmann L, Jung HC, Schurer-Maly C, et al. Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8. Gastroenterology. 1993;105:1689-97.
58. Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun. 1993;61:4569-74.
59. Schüller S, Heuschkel R, Torrente F, et al. Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect. 2007;9:35-9.
60. Gobert AP, Vareille M, Glasser AL, et al. Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J Immunol. 2007;178:8168-74.
61. Tallant T, Deb A, Kar N, et al. Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-κB and proinflammatory gene program activation in intestinal epithelial cells. BMC Microbiol. 2004;4:33.
62. Khan MA, Kang J, Steiner TS. Enteroaggregative Escherichia coli flagellin-induced interleukin-8 secretion requires Toll-like receptor 5-dependent p38 MAP kinase activation. Immunology. 2004;112:651-60.
63. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410:1099-03
64. Kelly J, Oryshak A, Wenetsek M, et al. The colonic pathology of Escherichia coli O157:H7 infection. Am J Surg Pathol. 1990;14:87-92
65. Hurley BP, Thorpe CM, Acheson DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun. 2001;69:6148-55.
66. Wagner PL, Acheson DW, Waldor MK. Human neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect Immun. 2001;69,1934-37.
67. Karmali MA, Steele BT, Petric M, et al. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1:619-20.
68. Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol. 1995;9:117-9.
69. Jacewicz MS, Acheson DW, Mobassaleh M, et al. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest. 1995;96:1328-35.
70. Eklund M, Leino K, Siitonen A. Clinical Escherichia coli strains carrying stx genes: stx variants and stxpositive virulence profiles. J Clin Microbiol. 2002;40:4585-93.
71. Ethelberg S, Olsen KE, Scheutz F, et al. Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect Dis. 2004;10:842-47.
72. Melton-Celsa AR, Kokai-Kun JF, O'Brien AD. Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer. Mol Microbiol. 2002;43:207-15.
73. Rivas M, Miliwebsky E, Chinen I, et al. The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission. Medicina (B Aires). 2006;66:27-32.
74. Ling H, Boodhoo A, Hazes B, et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777-88.
75. Soltyk AM, MacKenzie CR, Wolski VM, et al. A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. J Biol Chem. 2002;277:5351-59.
76. O'Loughlin EV, Robins-Browne RM. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect. 2001;3:493-07.
77. Hanashima T, Miyake M, Yahiro K, et al. Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells. Microb Pathog. 2008;45:124-33.
78. Iversen TG, Skretting G, Llorente A, et al. Endosome to Golgi transport of ricin is independent of clathrin and of the Rab9- and Rab11-GTPases. Mol Biol Cell. 2001;12:2099-07.
79. Sandvig K, Grimmer S, Lauvrak SU, et al. Pathways followed by ricin and Shiga toxin into cells. Histochem Cell Biol. 2002;117:131-41.
80. Römer W, Berland L, Chambon V, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature. 2007;450:670-75.
81. Sandvig K, Garred O, Prydz K, et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 1992;358:510-12.
82. Sandvig K, van Deurs B. Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin. FEBS Lett. 2002;529:49-53.
83. Garred O, Van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995;270:10817-21.
84. Lea N, Lord JM, Roberts LM. Proteolityc cleavage of the A subunit is essentials for maximal cytotoxicity of Escherichia coli O157:H7 Shiga-like toxin-1. J Microbiol. 1999;145:999-04.
85. O'Brien AD, Tesh VL, Donohue-Rolfe A, et al. Shiga toxin: biochemistry, genetics, mode of action and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65-94.
86. Sandvig K, Van Deurs. B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996;76:949-66.
87. Brigotti M, Alfieri R, Sestili P, et al. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 2002;16:365-72.
88. Obrig TG. Shiga toxin mode of action in E. coli O157:H7 disease. Front Biosci. 1997;2:d635-d642.
89. Cherla RP, Sang-Yun L, Tesh VL. Shiga toxins and apoptosis. FEMS Microbiol Lett. 2003;228:159-66.
90. Taga S, Carlier K, Mishal Z, et al. Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood. 1997;90:2757-67.
91. Mangeney MCA, Lingwood S, Taga B, et al. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314-19.
92. Kojio S, Zhang H, Ohmura M, et al. Caspase-3 activation and apoptosis induction coupled with the retrograde transport of shiga toxin: inhibition by brefeldin A. FEMS Immunol Med Microbiol. 2000;29:275-81.
93. Williams JM, Lea N, Lord JM, et al. Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol Lett. 1997;91:121-27.
94. Pistone Creydt V, Silberstein C, Zotta E, et al. Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. Microbe Infec. 2006;8:410-19.
95. Marcato P, Mulvey G, Read RJ, et al. Immunoprophylactic potential of cloned Shiga toxin 2B subunit. J Infect Dis. 2001;183:435-43.
96. Lingwood CA. Verotoxin-binding in human renal sections. Nephron 1994; 66: 21-28.
97. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995;48:2-19.
98. Ray PE, Liu XH. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol. 2001;16:823-39.
99. van Setten PA, van Hinsbergh VW, van der Velden TJ, et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int. 1997;51:1245-56.
100. Richardson SE, Karmali MA, Becker LE, et al. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing E coli. Hum Pathol. 1988;19:1102-08.
101. Kaplan BS. Shiga toxin-induced tubular injury in hemolytic uremic syndrome. Kidney Int. 1998;54:648-49.
102. Hughes AK, Stricklett PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubules cells. Kidney Int. 1998;54:426-37.
103. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of renal cortical cells in the hemolitic-uremic syndrome: in vivo and in vitro studies. Infect Immun. 1998;66:636-44.
104. Nestoridi E, Kushak RI, Duguerre D, et al. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int. 2005;67:2254-66.
105. Takeda T, Dohi S, Igarashi T, et al. Impairment by verotoxin of tubular function contributes to the renal damage seen in haemolytic uraemic syndrome. J Infect. 1993;27:339-341.
106. Taylor FB Jr, Tesh VL, DeBault L, et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol. 1999;154:1285-99.
107. Zotta E, Lago N, Ochoa F, et al. Development of an experimental hemolytic uremic syndrome in rats. Pediatr Nephrol. 2008:23:559-67.
108. Karpman D, Andreasson A, Thysell H, et al. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, Pediatr Nephrol. 1995:9:694-99.
109. van Setten PA, van Hinsbergh VW, van den Heuvel LP, et al. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome. Pediatr Res. 1998;43:759-67.
110. Diamond JM, Bossert WH. Standing gradient osmotic flow. A mechanism for coupling of water and solute transport in epithelia. J Gen Physiol. 1967;50:2062-83.
111. Larsen EH, Mobjerg N, Sorensen JN. Fluid transport and ion fluxes in mammalian kidney proximal tubule: a model analysis of isotonic transport. Acta Physiol (Oxf). 2006;187:177-89.
112. Schnermann J, Chou CL, Ma T, et al. Defective proximal tubule reabsorptive capacity in transgenic aquaporin-1 null mice. Proc Natl Acad Sci. USA. 1998:95:.9660-64.
113. Carpi-Medina P, Whittembury G. Comparison of transcellular and transepithelial water osmotic permeabilities (Posm) in the isolated proximal straight tubule (PST) of the rabbit kidney. Pflugers Arch. 1988;412:66-74.
114. Nielsen S, Agre P. The aquaporin family of water channels in kidney. Kidney Int. 1995;48:1057-68.
115. Silberstein C, Pistone Creydt V, Gerhardt E, et al. Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2. Pediatr Nephrol. 2008;23:1981-90.
116. Siegler RL Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr. 1994;125:511-18.
117. Gallo EG, Gianantonio CA. Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol. 1995;9:117-19.
118. Fujii J, Kita T, Yoshida S, et al. Direct evidence of neuron impairment by oral infection with verotoxinproducing Escherichia coli O157: H- in mitomycin-treated mice. Infect Immun. 1994;62:447-53.
119. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun. 1996;64:5053-60.
120. Mizuguchi M, Sugatani J, Maeda T, et al. Cerebrovascular damage in young rabbits after intravenous administration of Shiga toxin 2. Acta Neuropathol. 2001;102:306-12.
121. Landoni VI, Campos-Nebel M, Schierloh P, et al. Shiga toxin 1-induced inflammatory response in LPSsensitized astrocytes is mediated by endogenous TNF-(alpha). Infect Immun. 2010:78:1193-201.
122. Mizuguchi M, Tanaka S, Fujii I, et al. Neuronal and vascular pathology produced by verocytotoxin in the rabbit central nervous system. Acta Neuropathol. 1996;91:254-62.
123. Takahashi K, Funata N, Ikuta F, et al. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflammation. 2008;5:11.
124. Goldstein J, Loidl CF, Pistone Creydt V, et al. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res. 2007;1161:106-15.
125. Boccoli J, Loidl CF, Lopez-Costa JJ, et al. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res. 2008;1230:320-33.
126. Gyles CL. Shiga toxin-producing Escherichia coli: an overview. J Anim Sci. 2007;85:13 Suppl:E45-E62.
127. Coombes BK, Wickham ME, Mascarenhas M, et al. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains. Appl Environ Microbiol. 2008;74:2153-60.
128. Bielaszewska M, Friedrich AW, Aldick T, et al. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis. 2006;43:1160-67.
129. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl. 2009;112:S4-7.
130. Taneike I, Zhang HM, Wakisaka-Saito N, et al. Enterohemolysin operon of Shiga toxin-producing Escherichia coli: a virulence function of inflammatory cytokine production from human monocytes. FEBS Lett. 2002;524:219-24.
131. Grys TE, Siegel MB, Lathem WW, et al. The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect Immun. 2005;73:1295-03.
132. Dahan S, Wiles S, La Ragione RM, et al. EspJ is a prophage-carried type III effector protein of attaching and effacing pathogens that modulates infection dynamics. Infect Immun. 2005;73:679-86.
133. Paton AW, Srimanote P, Talbot UM, et al. A new family of potent AB cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med. 2004;200:35-46.
134. Wang H, Paton JC, Paton AW. Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum. J Inf Dis. 2007;196:1093-01.
135. Matsuura G, Morinaga N, Yahiro K, et al. Novel subtilase cytotoxin produced by Shiga-toxigenic Escherichia coli induces apoptosis in Vero cells via mitochondrial membrane damage. Infect Immun. 2009;77:2919-24.
136. Byres E, Paton AW, Paton JC, et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature. 2008;456:648-52.
137. Wolfson JJ, May KL, Thorpe CM, et al. Subtilase cytotoxin activates PERK, IRE1 and ATF6 endoplasmic reticulum stress-signalling pathways. Cell Microbiol. 2008;10:1775-86.
138. Paton AW, Beddoe T, Thorpe CM, et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature. 2006;443:548-52.
139. Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev. 1998;19:173-02.
140. Morinaga N, Yahiro K, Matsuura G, et al. Two distinct cytotoxic activities of subtilase cytotoxin produced by Shiga-toxigenic Escherichia coli. Infect Immun. 2007;78:488-96.
141. Bielaszewska M, Fell M, Greune L, et al. Characterization of cytolethal distending toxin genes and expression in shiga toxin-producing Escherichia coli strains of non-O157 serogroups. Infect Immun. 2004;72:1812-1816.
142. Palermo M, Alves-Rosa F, Rubel C, et al. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol. 2000;119:77-83.
143. Keepers TR, Psotka MA, Gross LK, et al. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol. 2006;17:3404-14.
144. Sauter KA, Melton-Celsa AR, Larkin K, et al. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection fro m lethal outcome by anti-Stx2 antibody. Infect Immun. 2008;76:4469-78.
145. Louise CB, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun. 1992;60:1536-43.
146. Tesh VL, Ramegowda B, Samuel JE. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun. 1994;62:5085-94.
147. Proulx F, Litalien C, Turgeon JP, et al. Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome. Am J Kidney Dis. 2000;35:29-34.
148. Ray P, Acheson D, Chitrakar R, et al. Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2002;13:699-07.
149. Proulx F, Toledano B, Phan V, et al. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res. 2002;52:928-34.
150. Yamamoto T, Nagayama K, Satomura K, et al. Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157. Nephron. 2000;84:326-32.
151. Karpman D, Manea M, Vaziri-Sani F, et al. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost. 2006;32:128-45.
152. Nevard CH, Jurd KM, Lane DA, et al. Activation of coagulation and fibrinolysis in childhood diarrhoeaassociated haemolytic uraemic syndrome. Thromb Haemost. 1997;78:1450-55.
153. Nolasco LH, Turner NA, Bernardo A, et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005;106:4199-09.
154. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolyticuremic syndrome. N Engl J Med. 2002:346:23-32.
155. Barrett TJ, Potter ME, Wachsmuth IK. Bacterial endotoxin both enhances and inhibits the toxicity of Shigalike toxin II in rabbits and mice. Infect Immun. 1989;57:3434-37.
156. Harel Y, Silva M, Giroir B, et al. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest. 1993;92:2110-16.
157. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365-76.
158. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol. 2000;190:343-48.
159. Walters MD, Matthei IU, Kay R, et al. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol. 1989;3:130-34.
160. Buteau C, Proulx F, Chaibou M, et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J. 2000;19:642-7.
161. Inward CD, Howie AJ, Fitzpatrick MM, et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr Nephrol. 1997;11:556-59.
162. Milford DV, Staten J, MacGreggor I, et al. Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen. Nephrol Dial Transplant. 1991;6:232-37.
163. Ishikawa N, Kamitsuji H, Murakami T, et al. Plasma levels of granulocyte elastase-alpha1-proteinase inhibitor complex in children with hemolytic uremic syndrome caused by verotoxin producing Escherichia coli. Pediatr Int. 2000;42:637-41.
164. Huber AR, Kunkel SL, Todd RF III, et al. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science. 1991;254:99-02.
165. Milford D, Taylor CM, Rafaat F, et al. Neutrophil elastases and haemolytic uraemic syndrome. Lancet. 1989;2:1153.
166. Fitzpatrick MM, Shah V, Trompeter RS, et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int. 1992;42:951-56.
167. Fernandez GC, Rubel C, Barrionuevo P, et al. Phenotype markers and function of neutrophils in children with hemolytic uremic syndrome. Pediatr Nephrol. 2002;17:337-44.
168. Fernandez GC, Gomez SA, Rubel CJ, et al. Impaired neutrophils in children with the typical form of hemolytic uremic syndrome. Pediatr Nephrol. 2005;20:1306-14.
169. Fernandez GC, Gomez SA, Ramos MV, et al. The functional state of neutrophils correlates with the severity of renal dysfunction in children with Hemolytic Uremic Syndrome. Pediatr Res. 2007;61:123-28.
170. Walters MD, Levin M, Smith C, et al. Intravascular platelet activation in the hemolytic uremic syndrome. Kidney Int. 1988;33:107-15.
171. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-86.
172. Foster GH, Tesh VL. Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha. J Leukoc Biol. 2002;71:107-14.
173. Geelen JM, van der Velden TJ, van den Heuvel LP, et al. Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatr Nephrol. 2007;22:1181-7
174. Westerholt S, Pieper AK, Griebel M, et al. Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome. Clin Diagn Lab Immunol. 2003;10:1090-95.
175. Ramos MV, Fernández GC, Patey N, et al. Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood. 2007;109:2438-45.
176. Fernandez GC, Ramos MV, Gomez SA, et al. Differential expression of function-related antigens on blood monocytes in children with hemolytic uremic syndrome. J Leukoc Biol. 2005;78:853-61.
177. Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000;30:1872- 83.
178. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun. 1998;66:636-44.
179. Dran GI, Fernandez GC, Rubel CJ, et al. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int. 2002;62:1338-48.
180. Fernandez, GC, Rubel C, Dran G, et al. Shiga toxin-2 induces neutrophilia and neutrophil activation in a murine model of hemolytic uremic syndrome. Clin Immunol. 2000;95:227-34.
181. Fernandez GC, Lopez MF, Gomez SA, et al. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin Exp Immunol. 2006;146:76-84.
182. Gomez SA, Fernandez GC, Camerano G, et al. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Clin Exp Immunol. 2005;139:65-73.
183. Keepers TR, Gross LK, Obrig TG. Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome. Infect Immun. 2007;75:1229-36.
184. Comerford I, Nibbs RJ. Post-translational control of chemokines: a role for decoy receptors? Immunol Lett. 2005;96:163-74.
185. Palermo MS, Alves Rosa MF, Van Rooijen N, et al. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin Exp Immunol. 1999;116:462-67.
186. Gomez SA, Fernandez GC, Vanzulli S, et al. Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome. Clin Exp Immunol. 2003;131:217-24.
187. te Loo DM, Monnens LA, van Der Velden TJ, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95:3396-02.
188. Brigotti M, Caprioli A, Tozzi AE, et al. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J Clin Microbiol. 2006;44:313-17.
189. Fukuda MN, Dell A, Oates JE, et al. Structures of glycosphingolipids isolated from human granulocytes. The presence of a series of linear poly-N-acetyllactosaminylceramide and its significance in glycolipids of whole blood cells. J Biol Chem. 1985;260:1067-82.
190. Geelen JM, van der Velden TJ, Te Loo DM, et al. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leukocytes. Nephrol Dial Transplant. 2007;22:749-55.
191. King AJ, Sundaram S, Cendoroglo M, et al. Shiga toxin induces superoxide production in polymorphonuclear cells with subsequent impairment of phagocytosis and responsiveness to phorbol esters. J Infect Dis. 1999;179:503-07.
192. Liu J, Akahoshi T, Sasahana T, et al. Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7. Infect Immun. 1999;67:6203-05.
193. Flagler MJ, Strasser JE, Chalk CL, et al. Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun. 2007;75:760-65.
194. Palermo MS, Exeni RA, Fernández GC. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev Anti Infect Ther. 2009;7:697-07. Review.
195. van Setten PA, Monnens LA, Verstraten RG, et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood. 1996;88:174-83.
196. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84:289-97.
197. Cummings RD, Bainton, DF, McEver, RP. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 1995;128:661-671.
198. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyteplatelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-37.
199. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10:335-50.